Current  	Current  	 JJ	O
antihyperglycemic  	antihyperglycemic  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
strategies  	strategies  	 NNS	I-NP
for  	for  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
type  	type  	 NN	O
2  	2  	 CD	O
diabetes  	diabetes  	 NN	O
mellitus  	mellitus  	 VBD	O
The  	The  	 DT	O
current  	current  	 JJ	O
epidemics  	epidemics  	 NN	O
of  	of  	 IN	O
excessive  	excessive  	 JJ	B-NP
weight  	weight  	 NN	I-NP
and  	and  	 CC	O
type  	type  	 NN	B-NP
2  	2  	 CD	I-NP
diabetes  	diabetes  	 NN	I-NP
mellitus  	mellitus  	 NNS	I-NP
( 	( 	 -LRB-	O
T2DM 	T2DM 	 NNP	B-NP
)  	)  	 -RRB-	O
cause  	cause  	 VB	O
significant  	significant  	 JJ	O
morbidity  	morbidity  	 NN	O
and  	and  	 CC	O
mortality 	mortality 	 NN	O
.  	.  	 .	O
T2DM  	T2DM  	 NNP	O
frequently  	frequently  	 RB	O
coexists  	coexists  	 VBN	O
with  	with  	 IN	O
excess  	excess  	 JJ	O
weight  	weight  	 NN	O
as  	as  	 IN	O
well  	well  	 RB	O
as  	as  	 IN	O
hypertension  	hypertension  	 NN	O
and  	and  	 CC	O
dyslipidemia 	dyslipidemia 	 NN	B-NP
,  	,  	 ,	O
placing  	placing  	 VBG	O
a  	a  	 DT	O
significant  	significant  	 JJ	O
percentage  	percentage  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
population  	population  	 NN	O
at  	at  	 IN	O
an  	an  	 DT	O
elevated  	elevated  	 JJ	O
risk  	risk  	 NN	O
of  	of  	 IN	O
cardiovascular  	cardiovascular  	 JJ	B-NP
disease 	disease 	 NN	I-NP
.  	.  	 .	O
Maintaining  	Maintaining  	 VBG	O
effective  	effective  	 JJ	O
glycemic  	glycemic  	 JJ	B-NP
control  	control  	 NN	I-NP
is  	is  	 VBZ	O
linked  	linked  	 VBN	O
with  	with  	 IN	O
a  	a  	 DT	O
diminished  	diminished  	 JJ	O
risk  	risk  	 NN	O
of  	of  	 IN	O
developing  	developing  	 VBG	O
microvascular  	microvascular  	 JJ	B-NP
complications 	complications 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
recent  	recent  	 JJ	O
studies  	studies  	 NNS	O
have  	have  	 VBP	O
shown  	shown  	 VBN	O
it  	it  	 PRP	O
may  	may  	 MD	O
also  	also  	 RB	O
reduce  	reduce  	 VB	O
overall  	overall  	 JJ	O
macro  	macro  	 JJ	B-NP
vascular  	vascular  	 JJ	I-NP
complications 	complications 	 NNS	I-NP
.  	.  	 .	O
Reduction  	Reduction  	 NN	O
of  	of  	 IN	O
associated  	associated  	 JJ	O
risk  	risk  	 NN	B-NP
factors 	factors 	 NNS	I-NP
,  	,  	 ,	O
including  	including  	 VBG	O
those  	those  	 DT	O
related  	related  	 VBN	O
to  	to  	 TO	O
excessive  	excessive  	 JJ	B-NP
weight 	weight 	 NN	I-NP
,  	,  	 ,	O
high  	high  	 JJ	O
blood  	blood  	 NN	O
pressure 	pressure 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
dyslipidemia 	dyslipidemia 	 NN	B-NP
,  	,  	 ,	O
are  	are  	 VBP	O
also  	also  	 RB	O
necessary  	necessary  	 JJ	O
to  	to  	 TO	O
meaningfully  	meaningfully  	 RB	O
decrease  	decrease  	 VB	O
cardiovascular  	cardiovascular  	 JJ	B-NP
risk 	risk 	 NN	I-NP
.  	.  	 .	O
Agents  	Agents  	 NNS	O
that  	that  	 WDT	O
can  	can  	 MD	O
improve  	improve  	 VB	O
glycemia  	glycemia  	 VBN	O
with  	with  	 IN	O
weight  	weight  	 NN	B-NP
neutrality  	neutrality  	 NNS	I-NP
or  	or  	 CC	O
weight  	weight  	 NN	B-NP
loss  	loss  	 NN	I-NP
could  	could  	 MD	O
offer  	offer  	 VB	O
additional  	additional  	 JJ	O
benefit  	benefit  	 NN	O
to  	to  	 TO	O
overweight  	overweight  	 VB	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
T2DM 	T2DM 	 CD	O
.  	.  	 .	O
Although  	Although  	 IN	O
the  	the  	 DT	O
major  	major  	 JJ	O
pathophysiologic  	pathophysiologic  	 JJ	B-NP
defects  	defects  	 NNS	I-NP
in  	in  	 IN	O
T2DM  	T2DM  	 NNP	O
are  	are  	 VBP	O
recognized  	recognized  	 VBN	O
to  	to  	 TO	O
be  	be  	 VB	O
beta-cell  	beta-cell  	 JJ	B-NP
dysfunction  	dysfunction  	 NN	I-NP
and  	and  	 CC	O
peripheral  	peripheral  	 JJ	B-NP
insulin  	insulin  	 NN	I-NP
resistance 	resistance 	 NN	I-NP
,  	,  	 ,	O
derangements  	derangements  	 VBG	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
incretin  	incretin  	 JJ	B-NP
system  	system  	 NN	I-NP
may  	may  	 MD	O
contribute  	contribute  	 VB	O
as  	as  	 RB	O
well 	well 	 RB	O
.  	.  	 .	O
Antidiabetes  	Antidiabetes  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
targeting  	targeting  	 VBG	O
this  	this  	 DT	O
system  	system  	 NN	O
include  	include  	 VBP	O
dipeptidyl  	dipeptidyl  	 JJ	B-NP
peptidase-4  	peptidase-4  	 NNP	I-NP
( 	( 	 -LRB-	O
DPP-4 	DPP-4 	 NNP	B-NP
)  	)  	 -RRB-	O
inhibitors  	inhibitors  	 NN	O
and  	and  	 CC	O
glucagon-like  	glucagon-like  	 NNP	B-NP
peptide-1  	peptide-1  	 NNP	I-NP
( 	( 	 -LRB-	O
GLP-1 	GLP-1 	 NNP	B-NP
)  	)  	 -RRB-	O
receptor  	receptor  	 NN	B-NP
agonists 	agonists 	 NN	I-NP
.  	.  	 .	O
Both  	Both  	 DT	O
classes  	classes  	 NNS	O
have  	have  	 VBP	O
been  	been  	 VBN	O
shown  	shown  	 VBN	O
to  	to  	 TO	O
significantly  	significantly  	 RB	O
reduce  	reduce  	 VB	O
hyperglycemia 	hyperglycemia 	 NNS	B-NP
.  	.  	 .	O
GLP-1  	GLP-1  	 NNP	B-NP
receptor  	receptor  	 NN	I-NP
agonists  	agonists  	 VBZ	O
also  	also  	 RB	O
promote  	promote  	 VB	O
significant  	significant  	 JJ	O
weight  	weight  	 NN	B-NP
loss  	loss  	 NN	I-NP
and  	and  	 CC	O
have  	have  	 VBP	O
potentially  	potentially  	 RB	O
beneficial  	beneficial  	 JJ	O
effects  	effects  	 NNS	O
on  	on  	 IN	O
cardiovascular  	cardiovascular  	 JJ	B-NP
risk  	risk  	 NN	I-NP
markers 	markers 	 NN	I-NP
.  	.  	 .	O
